IMI: how to boost European bureaucracy

Europe's Innovative Medicines Initiative (IMI) has launched seven new projects, with a total budget of more than 237 million euros, aimed at accelerating the development of safer and more effective drugs.

And the meaning is … to boost drug development! It is serious! A couple moments are very interesting in this connection:

1.       237 million is a huge amount but Big Pharma has much more. Money is not a critical resource for new drug development by Big Pharma.

2.       The projects will be controlled by Big Pharma – no one clever enough small agents (university or small company with good ideas) will disclose the ideas – once again, - if they are clever enough!

Therefore this initiative is worthless in terms of “boosting drug development”. But it is definitively perfect to boost European bureaucracy. And the whole initiative is a nice proof that Big Pharma is in a crisis and the modern paradigm is useless.